Eohilia denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Eohilia on Medical-Necessity Grounds

Eohilia (budesonide oral suspension) is an FDA-approved treatment for eosinophilic esophagitis (EoE). Aetna's medical-necessity denials for this drug typically arise when the plan's clinical policy team concludes the submitted documentation does not confirm that the patient meets all of the insurer's coverage criteria — for example, that EoE was diagnosed by an appropriately credentialed specialist using the diagnostic methods described in Aetna's own published clinical policy, or that conventional management approaches were adequately trialed first.

This type of denial is almost always appealable, and many are reversed when complete, well-organized documentation is submitted.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full-and-fair internal review under ERISA §503 (employer-sponsored plans) or your state's insurance code. Submit within the plan's stated deadline — typically 180 days from the denial notice.
• External review: Under ACA §2719, you may request an independent external review from an accredited IRO after exhausting internal appeals (or if the internal appeal is denied). The external reviewer's decision is binding on the plan. Most external reviews must be completed within 45 days; expedited external review (within 72 hours) is available when your health is at serious risk from delay.
• Expedited internal appeal: If waiting the standard timeframe would seriously jeopardize your health, request an expedited internal appeal; plans must respond within 72 hours.

## The Concrete Appeal Process

1. Request the complete denial letter and the specific clinical criteria Aetna applied. 2. Obtain Aetna's published clinical policy for Eohilia/EoE — this is the criteria-by-criteria checklist you must answer. 3. Gather your documentation package (see below). 4. Submit a written appeal with a cover letter mapping each policy criterion to a specific piece of your chart evidence. 5. If denied again, file for external review within the plan's posted deadline (generally within four months of the final internal denial).

## Documentation to Gather

• Confirmed EoE diagnosis: Endoscopy and biopsy report establishing the diagnosis per current gastroenterological/allergological standards; note the interpreting specialist's credentials.
• Prior treatment history: Dated records of any dietary elimination trials, proton-pump inhibitor courses, or other EoE-directed therapies, including start/stop dates and documented outcomes or intolerances.
• Current clinical severity: Recent symptom-severity documentation from chart notes, validated symptom questionnaires completed in the office, and any repeat endoscopy findings.
• Prescriber medical-necessity letter: A signed letter from the treating gastroenterologist or allergist explaining the diagnosis, why Eohilia is the appropriate next therapy, and why the patient meets each criterion in Aetna's coverage policy and the FDA-approved prescribing label.

## Criteria-Mapping Strategy

Print the exact list of requirements from (a) Aetna's current clinical policy for Eohilia and (b) the FDA-approved prescribing information. For each requirement, write a one- or two-sentence answer citing the specific chart date, test result, or clinical note that satisfies it. Presenting the appeal in this parallel format — criterion, then evidence — makes it straightforward for the reviewer to approve coverage and leaves no ambiguity about what has been documented.